TokenPost·
Lilly Says Retatrutide Reduced A1C and Produced Weight Loss in Phase 3 Trial
The company said the treatment reduced A1C, a biomarker associated with diabetes, alongside weight loss.
More news
- TokenPostMonness, Crespi, Hardt Raises Apple Price Target to $355
- TokenPostPepe Chart Setup Sets Hourly Breakout Level at $0.000005017
- TokenPostBrian Armstrong Says Base Is Getting Even Faster in Amplified Post
- Crypto BriefingRipple targets $900M annualized revenue as institutional adoption triples in 2026
- Crypto BriefingFrance moves to share Bitcoin trade data with tax authorities across 46 jurisdictions initially
- TokenPostEtsy Shares Rise as Sales and Active Buyers Increase, EBITDA Outlook Adjusted